All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Clinical comparison

Lanreotide (Somatuline) vs Octreotide (Sandostatin)

An educational, source-based comparison of Lanreotide (Somatuline) and Octreotide (Sandostatin) — how each peptide works, what it's researched for, and what to know before going deeper.

Somatostatin Analog · Oncology
Lanreotide (Somatuline)

Long-acting somatostatin analog for acromegaly and NETs.

Mechanism

Cyclic octapeptide somatostatin analog with high affinity for SSTR2 and SSTR5. Suppresses GH secretion and slows progression of gastroenteropancreatic neuroendocrine tumors.

Research areas
  • Acromegaly
  • Gastroenteropancreatic NETs
  • Carcinoid syndrome
Considerations
  • FDA-approved.
  • Monitor gallbladder, glucose, and thyroid function.
Full Lanreotide (Somatuline) profile →
Somatostatin Analog · Oncology
Octreotide (Sandostatin)

Synthetic somatostatin analog for acromegaly and neuroendocrine tumors.

Mechanism

An 8-amino-acid synthetic analog of somatostatin that binds somatostatin receptors (primarily SSTR2 and SSTR5), suppressing growth hormone, glucagon, insulin, and several gastrointestinal hormones. Longer half-life than native somatostatin enables therapeutic use.

Research areas
  • Acromegaly
  • Carcinoid syndrome
  • VIPomas
  • Variceal bleeding
  • Neuroendocrine tumors
Considerations
  • FDA-approved.
  • Gallstones, hyperglycemia, GI upset are common adverse effects.
Full Octreotide (Sandostatin) profile →

Lanreotide (Somatuline) vs Octreotide (Sandostatin) — Key differences

  • Class: Lanreotide (Somatuline) is classified as Somatostatin Analog · Oncology, while Octreotide (Sandostatin) is Somatostatin Analog · Oncology.
  • Primary research focus: Lanreotide (Somatuline)acromegaly; Octreotide (Sandostatin)acromegaly.
  • Tag: FDA-Approved · Endocrine vs FDA-Approved · Endocrine.

Related comparisons